131 related articles for article (PubMed ID: 15767790)
21. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
Zwitter M; Kovac V; Smrdel U; Vrankar M; Zadnik V
J Thorac Oncol; 2009 Sep; 4(9):1148-55. PubMed ID: 19546818
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.
Boccardo F; Rubagotti A; Canobbio L; Galligioni E; Sorio R; Lucenti A; Cognetti F; Ruggeri E; Landonio G; Baiocchi C; Besana C; Citterio G; De Rosa M; Calabresi F
Tumori; 1998; 84(5):534-9. PubMed ID: 9862512
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
Rini BI; Vogelzang NJ; Dumas MC; Wade JL; Taber DA; Stadler WM
J Clin Oncol; 2000 Jun; 18(12):2419-26. PubMed ID: 10856102
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
Ricci S; Galli L; Chioni A; Iannopollo M; Antonuzzo A; Francesca F; Vocaturo V; Selli C; Orlandini C; Conte P
Cancer; 2002 Oct; 95(7):1444-50. PubMed ID: 12237912
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
Park I; Lee HJ; Bae WK; Yoon S; Lee JL
Invest New Drugs; 2019 Dec; 37(6):1239-1246. PubMed ID: 31231787
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
28. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
[TBL] [Abstract][Full Text] [Related]
29. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study.
Donskov F; von der Maase H; Henriksson R; Stiemer U; Wersäll P; Nellemann H; Hellstrand K; Engman K; Naredi P
Ann Oncol; 2002 Mar; 13(3):441-9. PubMed ID: 11996477
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908.
Katakami N; Sugiura T; Nogami T; Yamamoto H; Negoro S; Nakano T; Okamoto N; Takada Y; Kodama K; Ariyoshi Y
Lung Cancer; 2004 Jan; 43(1):93-100. PubMed ID: 14698543
[TBL] [Abstract][Full Text] [Related]
32. [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
Xiong JP; Zhang L; Zhong LX; Qiu F; Guo YL; Lian HY; Luo H
Ai Zheng; 2006 Aug; 25(8):995-8. PubMed ID: 16965681
[TBL] [Abstract][Full Text] [Related]
33. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
Hsu C; Shen YC; Yang CH; Yeh KH; Lu YS; Hsu CH; Liu HT; Li CC; Chen JS; Wu CY; Cheng AL
Br J Cancer; 2004 May; 90(9):1715-9. PubMed ID: 15150619
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
Richey SL; Tamboli P; Ng CS; Lin E; Lim ZD; Araujo JC; Jonasch E; Sharma P; Pagliaro LC; Tannir NM
Am J Clin Oncol; 2013 Oct; 36(5):450-4. PubMed ID: 22706175
[TBL] [Abstract][Full Text] [Related]
35. Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Buti S; Lazzarelli S; Chiesa MD; Simonelli C; Re GL; Lheshi A; Simon S; Mattioli R; Caminiti C; Mazza G; Donini M; Passalacqua R;
J Immunother; 2010 Sep; 33(7):735-41. PubMed ID: 20664353
[TBL] [Abstract][Full Text] [Related]
36. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
37. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
38. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
Boorjian SA; Milowsky MI; Kaplan J; Albert M; Cobham MV; Coll DM; Mongan NP; Shelton G; Petrylak D; Gudas LJ; Nanus DM
J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529
[TBL] [Abstract][Full Text] [Related]
39. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G
Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508
[TBL] [Abstract][Full Text] [Related]
40. Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results.
Passardi A; Fanini F; Turci L; Foca F; Rosetti P; Ruscelli S; Casadei Gardini A; Valgiusti M; Dazzi C; Marangolo M
Oncologist; 2017 Aug; 22(8):886-e79. PubMed ID: 28592624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
